These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 23264358

  • 1. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
    van der Horst-Bruinsma IE, Zack DJ, Szumski A, Koenig AS.
    Ann Rheum Dis; 2013 Jul; 72(7):1221-4. PubMed ID: 23264358
    [Abstract] [Full Text] [Related]

  • 2. Associations between inflammation, nocturnal back pain and fatigue in ankylosing spondylitis and improvements with etanercept therapy.
    Hammoudeh M, Zack DJ, Li W, Stewart VM, Koenig AS.
    J Int Med Res; 2013 Aug; 41(4):1150-9. PubMed ID: 23803306
    [Abstract] [Full Text] [Related]

  • 3. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 4. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
    van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, Koenig AS.
    Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 6. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 7. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 15; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 9. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
    Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, Freundlich B.
    Arthritis Rheum; 2011 Jun 15; 63(6):1543-51. PubMed ID: 21630245
    [Abstract] [Full Text] [Related]

  • 10. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 15; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 11. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct 15; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 12. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.
    Ann Rheum Dis; 2010 Jun 15; 69(6):1065-71. PubMed ID: 19740906
    [Abstract] [Full Text] [Related]

  • 13. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X, Koenig AS, Jones H, Szumski A, Collier D, Bananis E.
    J Rheumatol; 2015 Aug 15; 42(8):1418-26. PubMed ID: 26077401
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 15; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 15. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

  • 16. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 02; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 17. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 02; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 18. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec 02; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 19. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep 02; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.
    Ann Rheum Dis; 2009 Apr 02; 68(4):531-5. PubMed ID: 18375542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.